T Cell Engagers: Revolutionizing Autoimmune Disease Treatment

Discover how bispecific T cell engagers are transforming the landscape of autoimmune disease treatment. Building on their proven success in oncology, these innovative therapies are now being adapted to target overactive B cells in autoimmune conditions, signaling a new era in precision medicine. With over $2.6 billion in deal-making activity in 2024 and 34 assets currently under development, the momentum is undeniable.

Download the infographic to explore the game-changing potential of TCEs and why pharma giants are betting big on this revolutionary approach.

T Cell Engagers for Autoimmune Disease Treatment Infographic

This infographic covers:

  • TCE Development & Trials: Gain insights into the latest advancements, from preclinical assets to clinical milestones.
  • B Cell Targets: Uncover the leading targets in the field and the rationale behind their selection.
  • Investments & Deals: Explore commercial activity over the past decade, with a spotlight on the record-breaking $2.6 billion invested in 2024.
  • Clinical Highlights: Learn about early successes, including promising trial results and use cases.

You May Also Be Interested In…

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search